-
公开(公告)号：US20240336608A1
公开(公告)日：2024-10-10
申请号：US18617907
申请日：2024-03-27
发明人： David A. Candito , Anthony Donofrio , Ronald Dale Ferguson, II , George Madalin Giambasu , Anmol Gulati , Andrew M. Haidle , Brett A. Hopkins , William P. Kaplan , Ping Liu , Michaelyn C. Lux , Xiao Mei Zheng , Ryan D. Otte , Alexander Pasternak , Elsie C. Yu
IPC分类号： C07D417/14 , A61K31/422 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/542 , A61K39/395 , C07D401/14 , C07D403/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/048 , C07D495/04 , C07D513/04
CPC分类号： C07D417/14 , A61K31/422 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/542 , A61K39/3955 , C07D401/14 , C07D403/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/048 , C07D495/04 , C07D513/04
摘要： Described herein are compounds of Formula I
or a pharmaceutically acceptable salt thereof, wherein R1, R2, A, and B are as defined herein. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.-
公开(公告)号：US20240287138A1
公开(公告)日：2024-08-29
申请号：US18429587
申请日：2024-02-01
发明人： Kaustav Biswas , Nicolas C. Boyer , Brandon D. Cash , Fa-Xiang Ding , John R. Frost , Michael B. Garrigou , James P. Jewell , Ahmet Kekec , Hu-Jung Julie Lee , Songnian Lin , Ashwin U. Rao , Daniel J. Sindhikara , Murray Wan , Yuping Zhu , Susan L. Zultanski , Tony Siu , Andrew M. Haidle , Claudio Mapelli , Luca Gambini , Federica Orvieto , Roberta Tozzi , Nicolo Maria Pasquini , Luigi Abate , Giordano Proietti , Michael Wuo , Ryan Chau
摘要： Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts,
can inhibit TNFR1 and are expected to have utility as therapeutic agents, for example, for treating inflammatory bowel diseases, rheumatoid arthritis, junvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of inflammatory bowel diseases, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa, and for preparing pharmaceuticals for this purpose.-
公开(公告)号：US11702430B2
公开(公告)日：2023-07-18
申请号：US17040192
申请日：2019-03-28
申请人： Merck Sharp & Dohme LLC , Michael D. Altman , Brandon D. Cash , Jared N. Cumming , Duane E. DeMong , Andrew M. Haidle , James P. Jewell , Matthew A. Larsen , Min Lu , Ryan D. Otte , Brandon M. Taoka , Benjamin Wesley Trotter , Quang T. Truong
发明人： Michael D. Altman , Brandon D. Cash , Jared N. Cumming , Duane E. DeMong , Andrew M. Haidle , James P. Jewell , Matthew A. Larsen , Min Lu , Ryan D. Otte , Brandon M. Taoka , Benjamin Wesley Trotter , Quang T. Truong
IPC分类号： C07D513/04 , C07D495/04 , C07D277/64 , A61P37/04 , A61P35/00
CPC分类号： C07D513/04 , A61P37/04 , C07D495/04
摘要： Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R5, R6, R8, R9, A, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.
-
-
搜索结果
3 条记录 (耗时 0.014 秒)
